https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease
belzutifan has been approved by the FDA. Approved for use for VHL associated cancers of neuroendocrine pancreatic tumours, haemangioblastomas of the CNS and RCC.
ORR for RCC was 49%. Belzutifan was acquired by Merck for initial payment of 1.1B with milestone payments up to 1.1b in 2019. I'm sure this approval would've been a milestone payment.
A good yardstick for Race as one of our indications is for ccRCC(same cancer as belzutifan is treating), which was it's lead candidate. They were given PRV in 2019. Open label P2 trial started in 2018 and i assume is ongoing (based off clinical.gov)
Industry news, page-78
-
- There are more pages in this discussion • 1,769 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |